{"id":612890,"date":"2026-09-11T03:15:44","date_gmt":"2026-09-11T03:15:44","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/612890\/interstitial-lung-disease-market-size-is-projected-to-grow-from-usd-6-billion-at-a-cagr-of-87-by-2036-delveinsight.html"},"modified":"2026-09-11T03:15:44","modified_gmt":"2026-09-11T03:15:44","slug":"interstitial-lung-disease-market-size-is-projected-to-grow-from-usd-6-billion-at-a-cagr-of-87-by-2036-delveinsight","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/612890\/interstitial-lung-disease-market-size-is-projected-to-grow-from-usd-6-billion-at-a-cagr-of-87-by-2036-delveinsight.html","title":{"rendered":"Interstitial Lung Disease Market Size is Projected to Grow from USD 6 Billion at a CAGR of 8.7% By 2036| DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789015438.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Interstitial Lung Disease Market Size is Projected to Grow from USD 6 Billion at a CAGR of 8.7% By 2036| DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789015438.jpg\" alt=\"Interstitial Lung Disease Market Size is Projected to Grow from USD 6 Billion at a CAGR of 8.7% By 2036| DelveInsight\" width=\"225\" height=\"124\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">Interstitial Lung Disease, also known as diffuse parenchymal lung disease, represents a heterogeneous group of lung disorders characterized by shared clinical, radiographic, physiologic, or pathologic features, with inflammatory and fibrotic processes extending beyond the interstitium to affect the alveoli, alveolar ducts, and bronchioles.<\/div>\n<p style=\"text-align: justify\">(Albany, US), September 10, 2026, DelveInsight&#8217;s &#8220;Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast &#8211; 2036&#8221; report offers an in-depth understanding of ILD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">To know in detail about the ILD market outlook, drug uptake, treatment scenario, and epidemiology trends:<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market<\/a><\/p>\n<p style=\"text-align: justify\">Some of the Key Facts of the Interstitial Lung Disease Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">In March 2026, United Therapeutics reported that the Phase III TETON-1 trial assessing inhaled treprostinil achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF), showing improvement in lung function (FVC) and supporting a potential expansion beyond PH-ILD into broader ILD indications.<\/p>\n<\/li>\n<li>\n<p>In May 2026, Brainomix and Boehringer Ingelheim expanded their strategic partnership to launch the PROGRESS-PPF study, a multi-site U.S. trial generating real-world evidence on whether Brainomix&#8217;s e-Lung AI software can support earlier diagnosis of progressive pulmonary fibrosis.<\/p>\n<\/li>\n<li>\n<p>In May 2026, aTyr Pharma provided a regulatory update following an FDA Type C meeting for efzofitimod in pulmonary sarcoidosis, confirming that data from the ongoing Phase 3 EFZO-FIT study could support a future marketing application.<\/p>\n<\/li>\n<li>\n<p>In March 2026, Trevi Therapeutics aligned with the FDA following a successful End-of-Phase 2 meeting for Haduvio (nalbuphine ER), establishing a development path into Phase 3 trials for IPF-related chronic cough.<\/p>\n<\/li>\n<li>\n<p>In January 2026, Boehringer Ingelheim selected Brainomix&#8217;s e-Lung AI imaging technology as a co-primary endpoint for the Phase 3 DROP-FPF trial evaluating nerandomilast.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s analysis, the Interstitial Lung Disease market size in the 7MM was valued at more than USD 6 billion in 2025 and is projected to reach approximately USD 13 billion by 2036, expanding at a CAGR of 8.7% during the forecast period.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for the largest ILD market share among the 7MM, with revenue of approximately USD 5 billion in 2025, while Japan&#8217;s ILD market exceeded USD 350 million in 2025.<\/p>\n<\/li>\n<li>\n<p>The total number of ILD diagnosed prevalent cases in the 7MM was approximately 1.3 million in 2025, with the US alone reporting nearly 520,000 diagnosed prevalent cases.<\/p>\n<\/li>\n<li>\n<p>In 2025, males represented about 44% of ILD cases in the US, whereas females accounted for roughly 56%; in Japan, males accounted for approximately 52% of cases and females about 48%.<\/p>\n<\/li>\n<li>\n<p>In 2025, sarcoidosis represented the most prevalent ILD subtype across EU4 and the UK, with approximately 180,000 diagnosed cases, followed by IPF with about 120,000 patients.<\/p>\n<\/li>\n<li>\n<p>The number of treated ILD cases in the United States was about 420,000 in 2025 and is projected to increase through 2036.<\/p>\n<\/li>\n<li>\n<p>In 2036, among all ILD therapies, the highest revenue is estimated to be generated by JASCAYD (nerandomilast tablets) in the 7MM.<\/p>\n<\/li>\n<li>\n<p>Key ILD Companies: United Therapeutics, Liquidia Corporation, Boehringer Ingelheim, Roche, GSK, Bristol-Myers Squibb, Insmed, and others.<\/p>\n<\/li>\n<li>\n<p>Key ILD Therapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO\/TYVASO DPI\/TREPROST), Nerandomilast (JASCAYD), Nintedanib capsules (OFEV), Seralutinib, L606, Treprostinil Palmitil Inhalation Powder (TPIP), Admilparant (BMS-986278), Belimumab (BENLYSTA), Efzofitimod, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Interstitial Lung Disease Overview<\/p>\n<p style=\"text-align: justify\">Interstitial Lung Disease, also known as diffuse parenchymal lung disease, represents a heterogeneous group of lung disorders characterized by shared clinical, radiographic, physiologic, or pathologic features, with inflammatory and fibrotic processes extending beyond the interstitium to affect the alveoli, alveolar ducts, and bronchioles.<\/p>\n<p style=\"text-align: justify\">Diagnosis requires a comprehensive, multidisciplinary approach integrating clinical history, physiologic assessment, imaging, laboratory evaluation, and, when necessary, tissue sampling, given the broad and overlapping clinical, radiologic, and histopathologic features across ILD subtypes.<\/p>\n<p style=\"text-align: justify\">ILD is more prevalent in men than in women overall, though regional gender distribution varies, and current therapies largely slow disease progression rather than reverse fibrosis, leaving significant unmet need for disease-modifying options.<\/p>\n<p style=\"text-align: justify\">Request for Unlocking the Sample Page of the &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">Interstitial Lung Disease Treatment Market<\/a>&#8220;<\/p>\n<p style=\"text-align: justify\">Interstitial Lung Disease Epidemiology<\/p>\n<p style=\"text-align: justify\">The ILD epidemiology section provides insights into the historical and current ILD patient pool and forecasted trends across the seven major markets (7MM): the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan for the study period 2022&ndash;2036.<\/p>\n<p style=\"text-align: justify\">ILD Epidemiology Segmentation<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Interstitial Lung Disease Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li>\n<p>Interstitial Lung Disease Gender-specific Cases<\/p>\n<\/li>\n<li>\n<p>Interstitial Lung Disease Type-specific Cases<\/p>\n<\/li>\n<li>\n<p>Interstitial Lung Disease Treated Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Download the report to understand which factors are driving <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">ILD market trends<\/a><\/p>\n<p style=\"text-align: justify\">Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities<\/p>\n<p style=\"text-align: justify\">The drugs uptake section focuses on the rate of uptake of potential ILD drugs expected to launch during the forecast period 2026&ndash;2036, covering peak performance, factors affecting growth years, patient uptake by therapy, and anticipated sales.<\/p>\n<p style=\"text-align: justify\">The ILD treatment market size is anticipated to experience growth during the forecast period due to promising emerging treatment options that include admilparant (BMS-986278), seralutinib, L606, treprostinil palmitil inhalation powder (TPIP), and others, alongside continued strong uptake of premium antifibrotics and pulmonary hypertension-targeted agents such as OFEV and TYVASO\/TYVASO DPI.<\/p>\n<p style=\"text-align: justify\">The report also covers <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">Interstitial Lung Disease Pipeline Development Activities<\/a><\/p>\n<p style=\"text-align: justify\">ILD Marketed Therapies<\/p>\n<p style=\"text-align: justify\">Currently, the landscape is anchored by approved antifibrotic and inhaled prostacyclin therapies, alongside recently approved oral disease-modifying options, though no curative treatments are yet available.<\/p>\n<ul style=\"text-align: justify\">\n<li>Treprostinil (TYVASO\/TYVASO DPI\/TREPROST): United Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify\">An inhaled prostacyclin analogue approved for PAH and PH-ILD that promotes pulmonary vasodilation and inhibits platelet aggregation to improve exercise capacity; marketed in the US since 2021\/2022 and Japan since 2024.<\/p>\n<ul style=\"text-align: justify\">\n<li>Treprostinil (YUTREPIA): Liquidia Corporation<\/li>\n<\/ul>\n<p style=\"text-align: justify\">An oral inhalation prostacyclin agonist approved in the US in 2025 for PH-ILD.<\/p>\n<ul style=\"text-align: justify\">\n<li>Nerandomilast (JASCAYD): Boehringer Ingelheim<\/li>\n<\/ul>\n<p style=\"text-align: justify\">An oral phosphodiesterase-4 inhibitor approved in the US in December 2025 for progressive pulmonary fibrosis, modulating intracellular inflammatory and fibrotic signaling pathways.<\/p>\n<ul style=\"text-align: justify\">\n<li>Nintedanib Capsules (OFEV): Boehringer Ingelheim<\/li>\n<\/ul>\n<p style=\"text-align: justify\">An oral tyrosine kinase inhibitor targeting key pathways driving lung fibrosis, approved for IPF, systemic sclerosis-associated ILD, and other chronic fibrosing ILDs with a progressive phenotype.<\/p>\n<p style=\"text-align: justify\">ILD Emerging Therapies<\/p>\n<ul style=\"text-align: justify\">\n<li>Belimumab (BENLYSTA): GSK<\/li>\n<\/ul>\n<p style=\"text-align: justify\">A BLyS-specific inhibitor monoclonal antibody in late-stage Phase II\/III and Phase III trials for SSc-ILD and CTD-ILD, reflecting growing interest in B-cell-targeted immunomodulation.<\/p>\n<ul style=\"text-align: justify\">\n<li>Treprostinil Palmitil Inhalation Powder (TPIP): Insmed<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Phase III oral inhalation prostacyclin receptor agonist candidate for PH-ILD.<\/p>\n<ul style=\"text-align: justify\">\n<li>Seralutinib: Gossamer Bio\/Chiesi Farmaceutici<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Phase III oral inhalation PDGFR, CSF1R, and c-KIT inhibitor for PH-ILD, with anticipated US launch in 2030.<\/p>\n<ul style=\"text-align: justify\">\n<li>L606: Liquidia Corporation<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Phase III inhaled prostacyclin (IP receptor) agonist for PH-ILD.<\/p>\n<p style=\"text-align: justify\">Discover more about therapies set to shape the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">ILD market share<\/a><\/p>\n<p style=\"text-align: justify\">Interstitial Lung Disease Market Drivers<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Rising prevalence of pulmonary fibrosis, autoimmune-associated ILD, and occupational lung disorders.<\/p>\n<\/li>\n<li>\n<p>Growing aging population more susceptible to chronic respiratory diseases.<\/p>\n<\/li>\n<li>\n<p>Advancements in diagnostic technologies, including high-resolution CT and biomarker-based diagnostics.<\/p>\n<\/li>\n<li>\n<p>Increasing adoption of antifibrotic therapies such as nintedanib and pirfenidone.<\/p>\n<\/li>\n<li>\n<p>Strong pipeline of emerging therapies targeting fibrosis, inflammation, and immune dysregulation.<\/p>\n<\/li>\n<li>\n<p>Expanding role of precision medicine and phenotype-specific therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Interstitial Lung Disease Market Barriers<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Limited disease-modifying options beyond slowing fibrosis for several ILD subtypes.<\/p>\n<\/li>\n<li>\n<p>High treatment burden and poor long-term tolerability of chronic daily oral antifibrotics.<\/p>\n<\/li>\n<li>\n<p>Inadequate stratification across heterogeneous ILD subtypes.<\/p>\n<\/li>\n<li>\n<p>Lack of noninvasive biomarkers for early diagnosis and monitoring.<\/p>\n<\/li>\n<li>\n<p>Device-dependent administration burdens for inhaled prostacyclin therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Scope of the Interstitial Lung Disease Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Study Period: 2022&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Forecast Period: 2026&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Coverage: 7MM<\/p>\n<\/li>\n<li>\n<p>Key Interstitial Lung Disease Companies: United Therapeutics, Liquidia Corporation, Boehringer Ingelheim, Roche, GSK, Bristol-Myers Squibb, Insmed, and other emerging market players.<\/p>\n<\/li>\n<li>\n<p>Key Interstitial Lung DiseaseTherapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO\/TYVASO DPI\/TREPROST), Nerandomilast (JASCAYD), Nintedanib capsules (OFEV), Seralutinib, L606, Treprostinil Palmitil Inhalation Powder (TPIP), Admilparant (BMS-986278), Belimumab (BENLYSTA), Efzofitimod, and other emerging therapies.<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment: Comprehensive analysis of currently marketed and emerging ILD therapies.<\/p>\n<\/li>\n<li>\n<p>Market Dynamics: Detailed evaluation of market drivers, barriers, opportunities, and challenges.<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT analysis, product attribute analysis, cost assumptions and pricing analogues, reimbursement landscape, and competitive benchmarking.<\/p>\n<\/li>\n<li>\n<p>Additional Coverage: ILD unmet needs, KOL insights, market access strategies, and reimbursement analysis across the 7MM.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Contact Information<\/p>\n<p style=\"text-align: justify\">Company Name: DelveInsight Business Research LLP<\/p>\n<p style=\"text-align: justify\">Contact Person: Mehul Malhotra<\/p>\n<p style=\"text-align: justify\">Email: info@delveinsight.com<\/p>\n<p style=\"text-align: justify\">Phone: +1 469 945 7679<\/p>\n<p style=\"text-align: justify\">Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States<\/p>\n<p style=\"text-align: justify\">Website: DelveInsight Consulting<\/p>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_98558.html\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Mehul Malhotra<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=interstitial-lung-disease-market-size-is-projected-to-grow-from-usd-6-billion-at-a-cagr-of-87-by-2036-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>A-1  NV 89107<br \/><strong>City:<\/strong> delhi<br \/><strong>State:<\/strong> Indiana<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=interstitial-lung-disease-market-size-is-projected-to-grow-from-usd-6-billion-at-a-cagr-of-87-by-2036-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Interstitial Lung Disease, also known as diffuse parenchymal lung disease, represents a heterogeneous group of lung disorders characterized by shared clinical, radiographic, physiologic, or pathologic features, with inflammatory and fibrotic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/612890"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=612890"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/612890\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=612890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=612890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=612890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}